- Company
- Pfizer’s Zavicefta, sole CRE antibiotic in KOR, gets reimb
- by Son, Hyung-Min Feb 22, 2024 05:49am
- A new antibiotic has been added to the insurance reimbursement listing a year after Zerbaxa. Zavicefta, developed by Pfizer, is the only antibiotic that can be used to treat carbapenem-resistant Enterobacteriaceae (CRE). Experts have stressed the use of this drug only when necessary because there is a growing number of patients with antibi
- Company
- K-made anticancer drugs Leclaza, Rolontis show sales growth
- by Chon, Seung-Hyun Feb 22, 2024 05:49am
- New anticancer drugs developed by Korean pharmaceutical companies are showing a steady growth path in the market. Yuhan’s Leclaza, a lung cancer treatment, surpassed 20 billion won in annual sales, becoming the first domestically developed anticancer drug to achieve this. Hanmi’s Rolontis, a treatment for neutropenia, reached 10 billion won in
- Company
- K-CAB and Fexuclue, new P-CAB drugs, expand globally
- by Kim, Jin-Gu Feb 21, 2024 05:45am
- New P-CAB class drugs, K-CAB (tegoprazan) and Fexuclue (fexuprazan), for treating gastroesophageal reflux disease are competing for global entries. HK inno.N’s K-CAB has entered 35 countries globally through technology exports or finished product exports. Within a year of its launch, Daewoong Pharmaceutical’s Fexuclue has been introd
- Company
- Sanofi Korea CEO Kyungeun Bae promoted to head 3 countries
- by Eo, Yun-Ho Feb 21, 2024 05:45am
- Sanofi-Aventis Korea’s Country Manager, Kyungeun Bae(53) is continuing on her prosperous career path. Dailypharm’s coverage found that Bae (Sanofi Korea Country Lead) was recently appointed as the general manager to lead subsidiaries including Korea, New Zealand, and Australia of the Sanofi Group. This is the first time a Korean has bee
- Company
- Keytruda leads mkt for 4 consecutive years
- by Chon, Seung-Hyun Feb 21, 2024 05:45am
- The immuno-oncology drug Keytruda has taken the lead in the domestic market for the 4th consecutive year. Its quarterly sales exceeded KRW 100 billion for the first time in the domestic market after being expanded reimbursement to the first line. The gap with the runner-up had more than doubled, reinforcing Keytruda’s leadership in the market.
- Company
- Samsung Bioepis will directly sell 3 of its biosimilars
- by Nho, Byung Chul Feb 20, 2024 06:00am
- Samsung Bioepis is expected to strengthen its sales and marketing force and network and switch to direct domestic sales of its 3 self-developed biosimilars. According to industry sources, Samsung Bioepis will directly sell 3 of its biosimilars for autoimmune diseases (TNF-alpha inhibitors) in the domestic market from next month (March).
- Company
- Generic Pazeo sales 24%↑ after patent dispute win
- by Kim, Jin-Gu Feb 20, 2024 06:00am
- Last year, generic products in the market for eye drops with the active ingredient olopatadine, used to treat allergic conjunctivitis, posted a 24% year-over-year (YoY) increase in prescription sales. It is the most significant sales expansion since 2019. The pharmaceutical industry anticipates a substantial expansion in prescription sales o
- Company
- K-Pharma Bios jump into cancer vaccine development
- by Son, Hyung-Min Feb 19, 2024 05:45am
- Cancer vaccine candidates produced by domestic pharmaceutical and biotech companies are now one step closer to conquering intractable cancers, demonstrating effect in clinical trials. DXVX's cancer vaccine candidate has shown an effect on ovarian cancer and lung cancer, and Aston Science has entered Phase II clinical trials for gastric can
- Company
- Clopidogrel mkt exceeds KRW 500 bil for the first time
- by Kim, Jin-Gu Feb 19, 2024 05:45am
- The antiplatelet market for clopidogrel has grown to exceed KRW 500 billion in Korea. Although 25 years have passed since the original drug, Sanofi's Plavix, was released in Korea, its market is still showing growth. Last year, the growth of generic products stood out in the market. The combined prescription sales of generic products incre
- Company
- K-made new stroke drugs accelerate towards commercialization
- by Son, Hyung-Min Feb 19, 2024 05:45am
- New candidate products for ischemic stroke developed by Korean pharmaceutical companies are proving to be effective. As global pharmaceutical companies have faced difficulties in development, attention is drawn to the possibility of commercializing new stroke drugs made in Korea. According to industry experts on the 17th, Phase 3 clinical dem
